Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

NCT06242470 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT06242470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06242470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors
Lead sponsor
MacroGenics
Phase
Phase 1
Overall status
Recruiting
Start date
March 6, 2024
Completion date
October 31, 2028
Enrollment
250 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumor, bladder cancer, breast cancer, castration resistant prostatic cancer, cervical cancer, clear cell renal cell carcinoma, colorectal cancer, endometrial cancer, esophageal squamous cell cancer (scc), gastric cancer, gastro-esophageal cancer, hepatocellular carcinoma, melanoma, metastatic cancer, non small cell lung cancer, ovarian cancer, pancreas cancer, platinum-resistant ovarian cancer, sarcoma, small-cell lung cancer, squamous cell carcinoma of head and neck